ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

silodosin

Also written as “Silodosin”, “KSO-0400” and “Silodosin Capsules”.

Its studies are mostly in Prostatic Hyperplasia · Nocturia · Lower Urinary Tract Symptoms · Ureteral Calculi · Ureterolithiasis, led by 6 companies.

Drug pageSilodosin: every studyMany companies study it; this page follows only the 17 they lead. All 40 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 14, 200517 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie60 open or runningphase 3since Sep 14, 2005Sep 14, 2005none ahead
JW Pharmaceuticalits history only50 open or runningphase 4since Oct 25, 2010Oct 25, 2010none ahead
Kissei Pharmaceuticalits history only20 open or runningphase 2since Oct 15, 2010Oct 15, 2010none ahead
RECORDATI GROUPits history only20 open or runningphase 4since Dec 21, 2012Aug 2, 2006none ahead
Shanghai Huilun Pharmaceuticalits history only10 open or runningphase 4since Aug 14, 2025Aug 14, 2025none ahead
Xintian Pharmaceuticalits history only10 open or runningphase 4since Sep 19, 2022Sep 19, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2005First studies: 3 phase 3 studies in Prostatic HyperplasiaFirst studyNCT00224133, NCT00224120, NCT00224107
  2. Aug 21, 2008Phase 2 study in ProstatitisNCT00740779 · 153 enrolled · United States
  3. Nov 17, 2008Phase 2 study in NocturiaNCT00793819 · 215 enrolled · United States
  4. Jun 14, 2010Phase 2 study in Ureteral CalculiNCT01144949 · 239 enrolled · United States

TargetBeta

ADRA1A →read by rule
“Alpha-1a adrenergic receptor antagonist”ChEMBL 37, by rule

Other programs on ADRA1A

ProgramCompanyFurthest phaseStudies
TamsulosinruleBoehringer Ingelheimphase 460
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
MidodrineruleTakedaphase 410
PrazosinrulePfizerphase 34

Studies

All 6 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01144949Ureteral Calculi · United States2CompletedJul 2012239
NCT00793819Nocturia · United States2CompletedOct 2009215
NCT00740779Prostatitis · United States2CompletedOct 2009153
NCT00224133Prostatic Hyperplasia · United States3CompletedApr 2007661
NCT00224120Prostatic Hyperplasia · United States3CompletedMay 2006462
NCT00224107Prostatic Hyperplasia · United States3CompletedAug 2006461

How it is read

Names in the registry

  • “Silodosin”, 12 entries
  • “silodosin”, 5 entries
  • “KSO-0400”, 2 entries
  • “Silodosin Capsules”, 1 entry
  • “Silodosin 8 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.